Navigation Links
Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial
Date:2/11/2008

MELBOURNE, Australia, Feb. 11 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH; AIM: PSG; OTCQX: PPGNY) and Nestle Nutrition (Nestle) today announced that their joint phase 2 human clinical trial to establish the efficacy of Phosphagenics' Phospha E(R) in the management of metabolic syndrome is advancing at three sites in Adelaide, Australia.

Based on current recruitment rates of study participants, the double-blind phase 2 trial, which is fully funded by Nestle, is expected to be completed in mid-2008.

This phase 2 clinical trial follows two pre-clinical dose response trials completed by Nestle and Phosphagenics in 2006. The results of those studies confirmed that, when given orally, Phospha E(R) significantly reduces many of the key biomarkers associated with metabolic syndrome.

Metabolic syndrome is characterized by a group of risk factors that increase the risk of diabetes, coronary heart disease and other diseases associated with plaque build up in artery walls.

The companies have agreed on the principal terms of a commercialization agreement, which will grant a worldwide exclusive license to Nestle for the use of Phospha E(R) in medical foods and for Phosphagenics to be the exclusive manufacturer and supplier of Phospha E(R) to Nestle. The final commercial agreement is due to be signed upon completion of the phase 2 trial.

Harry Rosen, President & CEO of Phosphagenics said: "We believe the agreed terms will deliver value to all parties and we look forward to building on the already strong relationship we have with Nestle, the world's largest food company."

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' core technology is built around t
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 The nation,s newest ... a Las Vegas courtroom.  Attorneys representing ... the men suffered severe effects, including death, after using the ... clients what they as a company knew, that their drug ... Robert Eglet .  "In order to hold Takeda responsible ...
(Date:8/27/2015)... Itamar Medical Ltd. (TASE:ITMR) and ... public equity (PIPE) deal, in which Viola Private Equity ...   Through this deal, Viola Private Equity ... will work closely with the company,s management to accelerate ... investment agreement, Itamar Medical will issue shares to Viola ...
(Date:8/27/2015)... , Aug. 27, 2015  Zimmer Biomet Holdings, Inc. ... healthcare, announced that it will be participating in the ... the Goldman Sachs offices in London ... the Company Founded in 1927 and headquartered in ... global leader in musculoskeletal healthcare.  We design, manufacture and ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
... Ingelheim Pharmaceuticals, Inc. will present new phase Ib data ... annual meeting in Chicago (June 3-7) that indicates combining ... the maximum tested dose controlled disease in all (n=22) ... non-small cell lung cancer (NSCLC) who developed acquired resistance ...
... NEW YORK, May 25, 2011 ... research report is available in its ... Devices Market Outlook in Brazil to ... Infusion Systems, Central Venous Catheters and ...
Cached Medicine Technology:Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 2Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 3Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 4Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 5Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 6Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC 7Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 2Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 3Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 4Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 5Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 6Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 7Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 8Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 9Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 10Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections 11
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of ... the Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and ... State University study. , While most people don’t develop persistent depression after a ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... today that its Krames Patient Education content is ICD-10 ready and available to ... for the new ICD-10 code sets, which are more targeted and return a ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... In addition ... Alvernia University now offers a third doctoral program at its main campus in Reading: ... a terminal degree program designed to prepare advanced practice nurses for the highest level ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... partnership agreement for quality market research promotion on the Internet. MarketPublishers.com is ... Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager at ...
(Date:8/27/2015)... ... , ... Sunbelt® Bakery, maker of delicious granola snacks that have a bakery-fresh ... how protein bars should taste with the launch of its new line of protein ... market today. , The new Protein Delights are individually wrapped wafer bars that ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... Fight for Healthy BabiesLONG BEACH and FOUNTAIN VALLEY, Calif., ... of MemorialCare Medical Centers and one of the nation,s ... named Southern California chair for the 2009 March for ... Southern California for his special interest in improving the ...
... Month and Change the Lives of Children and ... the nation,s largest non-profit provider of autism services, ... family members and professionals should have access to ... necessary services, supports and guidance at every life ...
... HL7 interoperability for the Department of Defense,s MiCare System at the IHE ... ... iNTERFACEWARE is pleased to announce that its Iguana HL7 ... of MiCare at the HIMSS Convention in Chicago next week. , ...
... With the Easter holiday fast approaching, tons of chocolate will soon be ... dark and milk chocolate and which is healthier for you. , ... ... tons of chocolate Easter Bunnies are unleashed on the world; given as ...
... free quotes for guaranteed issue health insurance plans for individuals who ... a major medical policy. , ... Dallas, TX (PRWEB) ... the addition of a new health plan available to all individuals ...
... (April 1, 2009) It appears that a drug ... similar effect on the compulsive behavior of kleptomaniacs it ... the University of Minnesota., The Medical School,s Department of Psychiatry ... ages 17-75, who spent an average of at least one ...
Cached Medicine News:Health News:Barry Arbuckle, Ph.D., President & CEO of MemorialCare Medical Centers to Chair Southern California March for Babies 2009, March of Dimes Largest Fundraising Events 2Health News:The Time to Act for Families is Now - Will You Act for Autism With Easter Seals? 2Health News:The Time to Act for Families is Now - Will You Act for Autism With Easter Seals? 3Health News:The Time to Act for Families is Now - Will You Act for Autism With Easter Seals? 4Health News:Iguana Selected for Department of Defense IHE Demonstration at HIMSS 09 2Health News:Iguana Selected for Department of Defense IHE Demonstration at HIMSS 09 3Health News:Poison Dressed as an Easter Bunny 2Health News:Free Quotes for Health Insurance Anyone Can Qualify For 2Health News:Free Quotes for Health Insurance Anyone Can Qualify For 3
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... 3 system consists of the Model 7432 ... MemoryMod Software Cartridge. , ,Enterra™ Therapy ... nausea and vomiting associated with gastroparesis when ... relief of symptons for diabetic or idiopathic ...
... Intramuscular Lead is a unipolar lead intended for ... has a ski needle design for easier use ... a fixed electrode length of 1 cm. The ... is available in 35 cm length. Two leads ...
Medicine Products: